(18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts

Mol Imaging Biol. 2012 Apr;14(2):237-44. doi: 10.1007/s11307-011-0491-5.

Abstract

Purpose: The objective of this study is to evaluate the therapeutic response to a novel monoclonal antibody targeting human extracellular matrix metalloproteinase inducer (EMMPRIN) in combination with gemcitabine in a pancreatic-tumor xenograft murine model by sequential 2-deoxy-2-[18F]fluoro-D-glucose ((18)F-FDG) positron emission tomography/computed tomgraphy (PET/CT) imaging.

Procedures: Four groups of SCID mice bearing orthotopic pancreatic tumor xenografts were injected with phosphate-buffered saline, gemcitabine (120 mg/kg BW), anti-EMMPRIN antibody (0.2 mg), or combination, respectively, twice weekly for 2 weeks, while (18)F-FDG PET/CT imaging was performed weekly for 3 weeks. Changes in mean standardized uptake value (SUV(mean)) of (18)F-FDG and volume of tumors were determined.

Results: The tumor SUV(mean) change in the group receiving combination therapy was significantly lower than those of the other groups. Tumor-volume changes of groups treated with anti-EMMPRIN monotherapy or combined therapy were significantly lower than that of the control group.

Conclusions: These data provide support for clinical studies of anti-EMMPRIN therapy with gemcitabine for pancreatic cancer treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Antibodies, Neoplasm / administration & dosage
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Basigin / immunology*
  • Cell Death / drug effects
  • Cell Line, Tumor
  • Contrast Media
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Deoxycytidine / therapeutic use
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Injections, Intravenous
  • Mice
  • Mice, SCID
  • Multimodal Imaging*
  • Pancreatic Neoplasms / diagnostic imaging
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Positron-Emission Tomography*
  • Tomography, Emission-Computed, Single-Photon
  • Tomography, X-Ray Computed*
  • Treatment Outcome
  • Xenograft Model Antitumor Assays*

Substances

  • Antibodies, Neoplasm
  • Contrast Media
  • Deoxycytidine
  • Fluorodeoxyglucose F18
  • Basigin
  • Adenosine Triphosphate
  • gemcitabine